Biotech Values

[DewDiligence]

NVS, which has had its problem with India’s legal system, faces new challenge from Cipla re Onbrez Breezhaler (approved for COPD):

http://in.reuters.com/article/2014/10/30/us-cipla-novartis-patent-idINKBN0IJ0U420141030

Cipla, India's fourth-largest drugmaker by revenue, said because there was an urgent but unmet need for the respiratory treatment in India it has started to sell a copy of the drug in Delhi priced at a fifth of the cost of Novartis's product.

…A senior official at the Indian government's Department of Industrial Policy and Promotion said Cipla's filing about Novartis's patents was made under Section 66 of the Indian Patents Act. The section grants the Indian government the power to revoke a patent in the public interest, after giving the patent holder an opportunity to explain why it should not be revoked…